Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company's board of directors.
Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis and delivery of care. Since starting her career at McKinsey & Company, she has over 25 years of experience as a venture investor, entrepreneur, consultant, and general manager at Rho Ventures, Cubit Software, Medtronic, Abbott Diabetes Care and Novartis Diagnostics. Through her work with multiple stakeholders, Kian has developed a systems-level view of the complex healthcare ecosystem. For the past 10 years she has led a specialized consulting firm advising Fortune 500 companies, startups and others in the areas of strategy, product development, business model innovation, commercialization, and monetization of novel opportunities across life sciences. She is currently a venture partner at Cota Capital, a multistage investment firm.
"We are delighted to welcome Kian to the board. She brings a wealth of vision and deep commercialization experience across diagnostics to her new role with the company. We are drawn to her commitment to leverage technology in improving healthcare and are eager to tap into her insights as we utilize AI and genomics in our mission to improve the diagnosis of infection," said Inflammatix CEO and Co-Founder Timothy Sweeney, MD, PhD.
Dr. Beyzavi added, "I'm thrilled to join the board. Inflammatix is poised to address important unmet needs in the diagnosis of acute illness, which will result in improved treatment decisions and outcomes. I look forward to working with this innovative team as they bring their breakthrough technologies to market."
Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient's immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company's initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Future tests will be developed to run on the company's sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, CA-based company is funded by leading medical technology investors including Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, and others. For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).
These press releases may also interest you